Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1994 Jun;96(3):476–483. doi: 10.1111/j.1365-2249.1994.tb06054.x

Growth and major histocompatibility antigen expression regulation by IL-4, interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) on human renal cell carcinoma.

G G Hillman 1, R K Puri 1, M A Kukuruga 1, J E Pontes 1, G P Haas 1
PMCID: PMC1534569  PMID: 8004818

Abstract

We have recently shown that human renal cell carcinoma (RCC) tumour lines express high-affinity IL-4 receptors. Binding of IL-4 to RCC cells induced a growth inhibition in the range of 20-68%. To enhance the growth inhibitory effect of IL-4, we have tested the effects of two additional cytokines capable of directly affecting tumour cell growth. IFN-gamma caused a significant inhibition of RCC tumour cell growth (up to 70%) in a dose-dependent manner, whereas the effect of TNF-alpha was more limited (0-20% inhibition). The addition of IL-4 to IFN-gamma on RCC cells sensitive to IL-4 induced a greater inhibition of cell growth than that seen with each cytokine alone. IL-4 and IFN-gamma rendered RCC cells more responsive to the inhibitory effect mediated by TNF-alpha. The combination of TNF-alpha with IL-4 and IFN-gamma induced an optimal growth inhibition (up to 90-98%) of RCC cells. In addition to a direct anti-proliferative effect, we have demonstrated that these cytokines can also enhance the expression of MHC antigens on the surface of RCC tumour cell lines which may render the cells more immunogenic. All RCC lines tested expressed class I antigens, but not class II antigens. IFN-gamma induced class II expression and up-regulated the expression of class I antigens on RCC cells. Class II antigen expression was detectable following 48 h incubation, and greater after 72 h with IFN-gamma. IL-4 minimally affected class I expression, whereas TNF-alpha up-regulated class I antigen expression. IL-4 or TNF-alpha did not induce class II expression. The combination of the three cytokines slightly augmented the up-regulation of class I and class II antigens observed with IFN-gamma alone. These observations confirm the direct interaction of IL-4, IFN-gamma and TNF-alpha with RCC tumour cells, both at the level of growth regulation and MHC antigen expression, and suggest a therapeutic potential of the combination of the three cytokines for renal cell carcinoma.

Full text

PDF
476

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aggarwal B. B., Eessalu T. E., Hass P. E. Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon. Nature. 1985 Dec 19;318(6047):665–667. doi: 10.1038/318665a0. [DOI] [PubMed] [Google Scholar]
  2. Aggarwal B. B., Eessalu T. E. Induction of receptors for tumor necrosis factor-alpha by interferons is not a major mechanism for their synergistic cytotoxic response. J Biol Chem. 1987 Jul 25;262(21):10000–10007. [PubMed] [Google Scholar]
  3. Cordon-Cardo C., Fuks Z., Drobnjak M., Moreno C., Eisenbach L., Feldman M. Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res. 1991 Dec 1;51(23 Pt 1):6372–6380. [PubMed] [Google Scholar]
  4. Farrar M. A., Schreiber R. D. The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol. 1993;11:571–611. doi: 10.1146/annurev.iy.11.040193.003035. [DOI] [PubMed] [Google Scholar]
  5. Fransen L., Van der Heyden J., Ruysschaert R., Fiers W. Recombinant tumor necrosis factor: its effect and its synergism with interferon-gamma on a variety of normal and transformed human cell lines. Eur J Cancer Clin Oncol. 1986 Apr;22(4):419–426. doi: 10.1016/0277-5379(86)90107-0. [DOI] [PubMed] [Google Scholar]
  6. Haas G. P., Hillman G. G., Redman B. G., Pontes J. E. Immunotherapy of renal cell carcinoma. CA Cancer J Clin. 1993 May-Jun;43(3):177–187. doi: 10.3322/canjclin.43.3.177. [DOI] [PubMed] [Google Scholar]
  7. Hashimura T., Tubbs R. R., Connelly R., Caulfield M. J., Trindade C. S., McMahon J. T., Galetti T. P., Edinger M., Sandberg A. A., Dal Cin P. Characterization of two cell lines with distinct phenotypes and genotypes established from a patient with renal cell carcinoma. Cancer Res. 1989 Dec 15;49(24 Pt 1):7064–7071. [PubMed] [Google Scholar]
  8. Hillman G. G., Haas G. P., Wahl W. H., Callewaert D. M. Adoptive immunotherapy of cancer: biological response modifiers and cytotoxic cell therapy. Biotherapy. 1992;5(2):119–129. doi: 10.1007/BF02171697. [DOI] [PubMed] [Google Scholar]
  9. Hoon D. S., Banez M., Okun E., Morton D. L., Irie R. F. Modulation of human melanoma cells by interleukin-4 and in combination with gamma-interferon or alpha-tumor necrosis factor. Cancer Res. 1991 Apr 15;51(8):2002–2008. [PubMed] [Google Scholar]
  10. Hoon D. S., Okun E., Banez M., Irie R. F., Morton D. L. Interleukin 4 alone and with gamma-interferon or alpha-tumor necrosis factor inhibits cell growth and modulates cell surface antigens on human renal cell carcinomas. Cancer Res. 1991 Oct 15;51(20):5687–5693. [PubMed] [Google Scholar]
  11. Lewis G. D., Aggarwal B. B., Eessalu T. E., Sugarman B. J., Shepard H. M. Modulation of the growth of transformed cells by human tumor necrosis factor-alpha and interferon-gamma. Cancer Res. 1987 Oct 15;47(20):5382–5385. [PubMed] [Google Scholar]
  12. Loeffler D. A., KuKuruga M. A., Juneau P. L., Heppner G. H. Analysis of distribution of tumor- and preneoplasia-infiltrating lymphocytes using simultaneous Hoechst 33342 labeling and immunophenotyping. Cytometry. 1992;13(2):169–174. doi: 10.1002/cyto.990130210. [DOI] [PubMed] [Google Scholar]
  13. Maio M., Gulwani B., Morgano A., Ferrone S. Differential modulation by tumor necrosis factor and immune interferon of HLA class-II antigens expressed by melanoma cells. Int J Cancer. 1989 Sep 15;44(3):554–559. doi: 10.1002/ijc.2910440330. [DOI] [PubMed] [Google Scholar]
  14. Mattijssen V., Van Moorselaar J., De Mulder P. H., Schalkwijk L., Ruiter D. J. Human leukocyte antigen expression in renal cell carcinoma lesions does not predict the response to interferon therapy. J Immunother (1991) 1992 Jul;12(1):64–69. doi: 10.1097/00002371-199207000-00008. [DOI] [PubMed] [Google Scholar]
  15. Morisaki T., Yuzuki D. H., Lin R. T., Foshag L. J., Morton D. L., Hoon D. S. Interleukin 4 receptor expression and growth inhibition of gastric carcinoma cells by interleukin 4. Cancer Res. 1992 Nov 1;52(21):6059–6065. [PubMed] [Google Scholar]
  16. Obiri N. I., Hillman G. G., Haas G. P., Sud S., Puri R. K. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J Clin Invest. 1993 Jan;91(1):88–93. doi: 10.1172/JCI116205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Obiri N. I., Siegel J. P., Varricchio F., Puri R. K. Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells. Clin Exp Immunol. 1994 Jan;95(1):148–155. doi: 10.1111/j.1365-2249.1994.tb06029.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Old L. J. Tumor necrosis factor. Sci Am. 1988 May;258(5):59-60, 69-75. doi: 10.1038/scientificamerican0588-59. [DOI] [PubMed] [Google Scholar]
  19. Pfizenmaier K., Scheurich P., Schlüter C., Krönke M. Tumor necrosis factor enhances HLA-A,B,C and HLA-DR gene expression in human tumor cells. J Immunol. 1987 Feb 1;138(3):975–980. [PubMed] [Google Scholar]
  20. Puri R. K., Leland P. Tumor necrosis factor upregulates interleukin-4 receptors on murine sarcoma cells. Biochem Biophys Res Commun. 1993 Dec 30;197(3):1424–1430. doi: 10.1006/bbrc.1993.2636. [DOI] [PubMed] [Google Scholar]
  21. Puri R. K., Siegel J. P. Interleukin-4 and cancer therapy. Cancer Invest. 1993;11(4):473–486. doi: 10.3109/07357909309018879. [DOI] [PubMed] [Google Scholar]
  22. Rosenberg S. A. Gene therapy of cancer. Important Adv Oncol. 1992:17–38. [PubMed] [Google Scholar]
  23. Schiller J. H., Bittner G., Storer B., Willson J. K. Synergistic antitumor effects of tumor necrosis factor and gamma-interferon on human colon carcinoma cell lines. Cancer Res. 1987 Jun 1;47(11):2809–2813. [PubMed] [Google Scholar]
  24. Sugarman B. J., Aggarwal B. B., Hass P. E., Figari I. S., Palladino M. A., Jr, Shepard H. M. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science. 1985 Nov 22;230(4728):943–945. doi: 10.1126/science.3933111. [DOI] [PubMed] [Google Scholar]
  25. Toi M., Bicknell R., Harris A. L. Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res. 1992 Jan 15;52(2):275–279. [PubMed] [Google Scholar]
  26. Topp M. S., Koenigsmann M., Mire-Sluis A., Oberberg D., Eitelbach F., von Marschall Z., Notter M., Reufi B., Stein H., Thiel E. Recombinant human interleukin-4 inhibits growth of some human lung tumor cell lines in vitro and in vivo. Blood. 1993 Nov 1;82(9):2837–2844. [PubMed] [Google Scholar]
  27. Totpal K., Aggarwal B. B. Interleukin 4 potentiates the antiproliferative effects of tumor necrosis factor on various tumor cell lines. Cancer Res. 1991 Aug 15;51(16):4266–4270. [PubMed] [Google Scholar]
  28. Tran R., Hand P. H., Greiner J. W., Pestka S., Schlom J. Enhancement of surface antigen expression on human breast carcinoma cells by recombinant human interferons. J Interferon Res. 1988 Feb;8(1):75–88. doi: 10.1089/jir.1988.8.75. [DOI] [PubMed] [Google Scholar]
  29. Tsujimoto M., Feinman R., Vilcek J. Differential effects of type I IFN and IFN-gamma on the binding of tumor necrosis factor to receptors in two human cell lines. J Immunol. 1986 Oct 1;137(7):2272–2276. [PubMed] [Google Scholar]
  30. Tungekar M. F., Turley H., Dunnill M. S., Gatter K. C., Ritter M. A., Harris A. L. Interleukin 4 receptor expression on human lung tumors and normal lung. Cancer Res. 1991 Jan 1;51(1):261–264. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES